Financial toxicity in gynecologic oncology

Bouberhan, Sara; Shea, Meghan; Kennedy, Alice; Erlinger, Adrienne L.; Stack-Dunnbier, Hannah; Buss, Mary K.; Moss, Laureen; Nolan, Kathleen F.; Awtrey, Christopher S.; Dalrymple, John L.; Garrett, Leslie; Liu, Fong W.; Hacker, Michele R.; Esselen, Katharine M.

doi:10.1016/j.ygyno.2019.04.003

Cited by 97 publications

(74 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To the best of our knowledge, the current study is the first to report the responsiveness of COST. The Chinese version showed significant differences between the values at baseline and after 6 months of therapy, indicating that the instrument is The median COST value was 18 in this study, which was lower than that of the J o u r n a l P r e -p r o o f previous studies with 23 to 29 in US patients 14,[23][24][25] and 22 in Japanese cancer patients. 26 Our study showed that younger age, lower household income and URBMI were associated with worse FT.…”

Section: Discussioncontrasting

confidence: 80%

The COmprehensive Score for financial Toxicity in China: Validation and Responsiveness

Zhong

et al. 2021

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussioncontrasting

confidence: 80%

The COmprehensive Score for financial Toxicity in China: Validation and Responsiveness

Zhong

et al. 2021

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

show abstract

“…Another study conducted among patients with gynaecological cancer also reported that women with financial hardship are seven times more likely to avoid or delay their cancer care. 25 Providing free diagnostic and treatment services to all women with cervical cancer needs to be incorporated into the government's strategy on cervical cancer care. This will be in line with the WHO's global efforts to ensure universal health coverage.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study

et al. 2020

View full text Add to dashboard Cite

ObjectiveTo describe the patterns and factors associated with advanced stage at diagnosis of cervical cancer among Addis Ababa residents, Ethiopia.DesignA population-based cross-sectional study.SettingSeven major hospitals or diagnostic facilities in Addis Ababa, Ethiopia.ParticipantsAll histopathology-confirmed patients with incident cervical cancer diagnosed from 1 January 2017 to 30 June 2018 among Addis Ababa residents.Outcome measuresThe proportion of patients with cervical cancer diagnosed at early stage (stage I/II) and advanced stage (stage III/IV) of the disease according to International Federation of Gynaecology and Obstetrics staging criteria, and adjusted prevalence ratio (APR) for factors associated with advanced-stage diagnosis using a Poisson regression with robust variance model.ResultsThe mean age of the study participants was 52.9 (±13.3) years. Nearly two-thirds (60.4%, 95% CI: 53.8% to 66.5%) of patients with cervical cancer were diagnosed at an advanced stage. Advanced stage at diagnosis was significantly associated with paying medical bill out of pocket (APR=1.44, 95% CI: 1.08 to 1.91), diagnostic interval >90 days (APR=1.31, 95% CI: 1.04 to 1.71), practicing religion as a remedy or not taking immediate action following symptom recognition (APR=1.25, 95% CI: 1.08 to 1.91) and visiting more than three different health facilities prior to diagnostic confirmation (APR=1.24, 95% CI: 1.07 to 1.51).ConclusionsOur findings of the high proportion of advanced-stage diagnosis of cervical cancer in Addis Ababa and its strong associations with out-of-pocket medical bill, seeking care out of conventional medicine settings and multiple visits to healthcare facilities before diagnostic confirmations underscore the need for public policies to improve the affordability of cancer care and enhance community awareness about the severity of the disease and referral system, in addition to expanding cervical cancer screening.

show abstract

“…In an attempt to quantify the experience of cancer patients related to financial difficulties during cancer treatment, the North American group Functional Assessment of Chronic Illness Therapy (FACIT) developed and validated [ 6 ] the COST questionnaire, with 11 items plus one considered a summary of all the questions. The answers are on a five-point Likert scale that measures the financial toxicity of the cancer patient, considered by some authors [ 11 , 12 ] as a side effect of cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Validation of the comprehensive score for financial toxicity for Brazilian culture

Nogueira¹,

Koller²,

Marcondes³

et al. 2020

ecancer

View full text Add to dashboard Cite

Financial toxicity is a side effect of cancer treatment showing the financial burden experienced by cancer patients for funding their treatment. An instrument for its evaluation can contribute towards the creation of coping strategies. In Brazil, a developing country, cancer patients certainly feel the effects of this serious adverse event, however, the discussion on the theme and research concerning these issues is scarce and an instrument for evaluation can help in the promotion of coping strategies. Thus, the study objective was to: 1) translate and adapt the COmprehensive Score for financial Toxicity (COST) questionnaire to Brazilian culture and 2) evaluate the COST psychometric properties in Brazil. Thus, a methodological study was developed in two stages. In the first stage, the translation and cross-cultural adaptation were performed, and in the second stage, two groups of participants were recruited to evaluate the psychometric properties. In the first stage, 21 individuals participated, including translators and cancer patients, and in the second stage, 126 patients participated who were undergoing cancer treatment. For validation, exploratory factor analysis (EFA), confirmatory factor analysis (CFA) and Cronbach’s alpha coefficient were performed to verify internal consistency. For the first stage’s outcome, the pre-test Cronbach’s alpha was 0.83. The EFA and CFA carried out in the second stage of the study revealed that the COST Brazilian version measures a single construct with a value of—χ2/gl = 179.78, comparative fit index = 0.00, Parsimony goodness of fit index = 0.302, root mean square error of approximation = 1.196 and p-value of close fit = 0.000. When comparing the average of the COST score and the standard deviation of the two samples, the significance value was p = 0.001. Therefore, it is possible to confirm that the COST is a valid and reliable questionnaire to measure the financial toxicity of cancer patients in Brazil.

show abstract

Financial toxicity in gynecologic oncology

Cited by 97 publications

References 18 publications

The COmprehensive Score for financial Toxicity in China: Validation and Responsiveness

The COmprehensive Score for financial Toxicity in China: Validation and Responsiveness

Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study

Validation of the comprehensive score for financial toxicity for Brazilian culture

Contact Info

Product

Resources

About